NEW YORK (Reuters Health) – Patients with pulmonary arterial hypertension (PAH) at intermediate risk of death within a year may be switched from a phosphodiesterase-5 (PDE-5) inhibitor to riociguat to reduce risk, researchers suggest. “Decision making regarding treatment of PAH has become increasingly complex,” Dr. Marius Hoeper of Hanover Medical School in Germany told Reuters